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Abstract
Complement receptor type 1 (CR1 or CD35) is a peripheral glycosylated membrane pro-
tein that regulates the complement activation in the control of immune responses. The 
author would like to overview the folding and binding properties of the soluble form of 
CR1, so-called as sCR1, introducing our development of the high-yield overexpression 
and purification methods as well as the investigation to its molecular structure. Although 
sCR1 prepared through our method showed the highest binding affinity against C3b, it 
is quite difficult to be crystallized for X-ray structure analysis. In spite of many attempts, 
only microcrystals have been obtained so far. Considering the usefulness to understand 
factors within the difficulty, the primary sequence of sCR1 has been reexamined from 
the viewpoints both of secondary structure predictions and recent findings of intrinsi-
cally disordered proteins (IDPs) or natively unfolded proteins (NUPs). As an example, the 
theoretically predicted structure of a short consensus repeat (SCR) of a binding domain, 
SCR-15–17 in sCR1 is compared with the reported solution structure by NMR. The discus-
sion is extended to protein structure studies with proteins containing ID regions, which 
are unfolded state without taking uniformly decided structures.
Keywords: complement receptor type1, CR1, sCR1, innate immunity, dissociation 
constant, binding affinity, overexpression, molecular structure, secondary structure 
prediction, crystallization
1. Introduction
Many cellular proteins are believed to fold autonomously to a certain specific three-dimensional 
structures in order to realize their unique biologically important functions [1, 2]. In the field of pro-
tein structural chemistry or structural biology, protein crystallography is fraught with challenge, 
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whereby various kinds of proteins are known to be difficult to be crystallized. The difficulty 
may be caused either by polymorphic conformations that the protein takes or movement of 
regions participating in the contact between molecules in a crystal field [3, 4].
On the other hand, wholly or partly unstructured proteins in vivo have been known for a long 
time and have been recently reevaluated and designated as intrinsically disordered proteins 
(IDPs) or natively unfolded proteins (NUPs) [5, 6]. It has been revealed that a large number 
of proteins contain at least a region that does not fold into uniformly converged sophisticated 
three-dimensional structures. Those regions are sometimes called random coils, which usu-
ally indicate globular proteins adopting an unfolded state. It is also not so rare for regions 
to form chain-like conformations as long as several hundred residues. Since the first review 
by Wright and Dyson [7], analyses by NMR studies and followed by computational analyses 
have revealed the importance of IDPs or NUPs in protein structural biochemistry. According 
to the recent computational survey of primary sequences, it is predicted that the total number 
of NUPs is approximately one-third of eukaryotic proteins [8].
From the viewpoint of studying functions of proteins, how to recognize and distinguish between 
self and non-self is still reminded mysterious. Recently, it has become apparent that extracellular 
membrane vesicles such as exosomes, released from cells are also involved in information trans-
mission between cells in the immune system as well as cancer metastasis [9–12]. In this chapter, 
the author would like to limit the subject protein to a complement regulatory peripheral mem-
brane protein of innate immunity. Immune adherence was first described at the beginning of 
the twentieth century and was rediscovered in the 1950s [13, 14]. The binding of serum-exposed 
particles to blood cells, which is a fundamental step for initiating and promoting the destruction 
of invasion microbes and for activating an adaptive immune system. This interaction is depen-
dent on the coating of the antigenic particle with the complement, and the recognition by a factor 
on the erythrocyte surface, namely the immune adherence receptor [15, 16]. Recently, not only 
infectious microorganisms such as Salmonella, pathogenic Escherichia coli, influenza virus and 
so forth but also causative substances of pollinosis and allergies are widely known as a trigger, 
further similar causes are increasing including artificial nanoparticles. The complement system, 
comprised of over 35 protein components present in the plasma or bound to cell surfaces, forms 
an integral part of the early innate immune response. Three major complement cascades such as 
classical-, alternative-, and mannose-binding lectin pathways are known to activate the comple-
ment pathway and for excluding harmful invaders.
Complement receptor type 1 (CR1 or CD35) is a glyco-membrane protein that plays a role as a 
regulator of complement activation in the control of immune responses through its binding to 
C3b/C4b-opsonized foreign antigens [17]. The existence of allotypes is known to CR1, and the 
molecular mass varies from 160 to 250 kDa depending on its types. The extracellular portion 
of the most common allotype has about molecular mass of 220 kDa and is comprised of 30 
modules, a series of tandem arranged short consensus repeat (SCR) (Figure 1). The sequence 
of each SCR shows approximately 45% homogeneity on average. The feature to be noted is the 
existence of four conserved cysteine residues in each SCR, as the first and third, and the sec-
ond and fourth cysteines from the N terminus are covalently linked through disulfide bonds 
[17]. Weisman et al. reported a construction of human CR1 plasmid (pBSCR1c/pTCSgpt) by 
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cloning a soluble CR1 gene to plasmid pTCSgpt, in which a stop codon was inserted before 
the transmembrane and cytoplasmic domains [18]. As shown in Figure 1, the schematic draw-
ing of the predicted structure of human sCR1 shows sCR1 consisting of four long homologous 
repeats (LHRs) constituted with seven SCRs, which are referred as LHR-A, -B, -C, and -D 
from N terminus. A binding domain to complement fragment C4b resides near N-terminus in 
LHR-A, and two domains to C3b reside LHR-B and LHR-C. The C3b binding domains appear 
to bind C4b but more weakly than C3b.
Although sCR1 may not fall exactly within the category of NUPs (or IDPs) because it has 
structured domains arranged at intervals tandemly, we think that it is important to consider 
the analysis of sCR1 from the perspective of NUPs (or IDPs).
2. Materials and methods
2.1. Preparation of human sCR1 from the cultivation with CHO cells
The cell line of Chinese hamster ovary (CHO) (CRL-10052) that carries the human sCR1 gene 
was purchased from American Type Culture Collection (ATCC) and was cultured under the 
ATCC’s instructions. The human sCR1 was overexpressed using our novel cell culture method 
comprised of two-stage cell culture of CHO cells expressing sCR1 [19, 20]. The first stage involves 
cells grow up to 70–80% confluent in the medium with fetal bovine serum (FBS), and during the 
second stage, the cells produce sCR1 extensively and secrete it in a serum-free medium. For the 
first stage of cell growth culture, cells were cultivated in a medium containing α-MEM (Sigma-
Aldrich Co. LLC., MO) supplemented with 10% FBS (Hyclone Lab. Inc., UT), 60 U/mL penicillin 
Figure 1. A schematic diagram showing the structural features of human sCR1. The extracellular domain consists of 
30 short consensus repeats (SCRs). The amino-terminal 28 SCRs constitute four long homologous repeats (LHRs). The 
regions of LHR-A through LHR-D are indicated in the brackets. The predicted binding domains to complement proteins 
C3b, and C4b are indicated, respectively. The inset shows the enlargement of the triple loop structure of SCR with the 
predicted disulfide bonds.
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and 60 μg/mL streptomycin (Pen Strep, Gibco, Life Technologies Corp., CA). Medium used for 
CHO cell culture was especially chosen, without deoxyribonucleoside and ribonucleoside. For 
the second stage of protein production, the cells were cultured in a serum-free medium such as 
ASF104 without albumin (Ajinomoto Co. Inc., Tokyo, Japan) supplemented with 1 μM metho-
trexate. Cell culture was performed in the incubator with 5% CO
2
 at 37°C.
The serum-free medium which contains the secreted human sCR1 was recovered after a fil-
tration (pore size of 0.22 μm). Subsequently, the purification of human sCR1 was performed 
by affinity column chromatography using HiTrap Heparin HP (GE Healthcare, PA). Briefly, 
the filtered medium solution was applied to the column that had been pre-equilibrated with 
20 mM Tris-HCl buffer (pH 7.5) containing 0.05% CHAPS (Dojindo Molecular Technologies, 
Inc., Kumamoto, Japan). The column was washed with the equilibration buffer containing 
100 mM NaCl, and the bound protein was eluted with 20 mM Tris-HCl buffer (pH 7.5) con-
taining 0.05% CHAPS and 200 mM NaCl. Each eluted fraction sample was examined with 
sodium dodecyl sulfate polyaclylamide gel electrophoresis (SDS-PAGE) and subsequent 
Coomassie Brilliant Blue (CBB) staining. Though in most cases, a single or a considerably 
major band which corresponds to human sCR1 can be observed at this stage, to achieve the 
buffer exchange concurrently and further examine the purity, the fractions containing sCR1 
gathered from the eluents from the heparin column was injected to HPLC gel filtration column 
chromatography (TSK gel G3000SWxl, Tosoh Corp., Tokyo, Japan). The single peak fraction 
at around the elution volume of 5.75 ml with a flow rate of 0.5 ml/min was collected as a puri-
fied human sCR1 [21]. Complement protein C3b was purchased from Calbiochem Research 
Biochemicals (EMD Bioscience, Inc., La Jolla, CA), and used after HPLC gel filtration column 
chromatography (TSK gel G3000SWxl, Tosoh Corp., Tokyo, Japan).
2.2. Characterization of binding affinity of sCR1 for C3b, and suppression effect of 
cell necrosis by sCR1
In order to investigate the binding affinity of the human sCR1 prepared by our protocol men-
tioned above, binding assay was performed by the use of a BIACORE X (GE Healthcare UK 
Ltd., Buckinghamshire, UK) using C3b as an analyte. The measurement was carried out using 
sCR1 as a ligand, immobilized on a substrate by the amine coupling method, and following 
the manufacturer’s operation manual. In addition, assuming heterogeneous ligand parallel 
reaction, data analysis was performed by the software, BIAevaluation attached to the device.
The suppression effect of sCR1 on complement activation was examined as follows: a stroma 
cell derived from mouse skull bone marrow was used for this assay. PA-6 cells were seeded 
and allowed to grow in the medium containing α-MEM (Sigma-Aldrich Co. LLC., MO) with 
10% FBS for 1 day. After three washes with PBS, cells were added with serum-free medium 
(900 μL of α-MEM) as well as 100 μL of PBS solution containing sCR1 and normal human 
serum (NHS) at a ratio of 1:9, or 100 μL of PBS solution containing sCR1 and heat-inactivated 
NHS at a ratio of 1:9. After 1 h incubation at 37°C, the suppression effect on the necrosis of cells 
was observed with a microscope (Zeiss Axiovert 200 M and Nikon DP50-WMED) following 
the previous methods [22–24].
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2.3. Crystallization trials
Crystallization using thus obtained human sCR1 was carried out with a normal sitting drop 
vapor diffusion technique in the combination with a random-screening protocol with screen 
packages such as the Hampton Crystal Screen, Hampton Crystal Screen II (Hampton Research, 
CA), and Structure Screen 1 and Structure Screen 2 (Molecular Dimensions, Suffolk, UK) after 
the condensation to the protein concentration of around 3.5 mg/mL by means of centrifugal 
concentrator (Centri-plus 20, Merck Millipore Corp., MA). The incubation temperature for the 
crystallization trials was kept at around 23°C [4, 25].
2.4. Secondary structure prediction of human sCR1
The secondary structure predictions of human sCR1 on the basis of its primary sequence 
were performed by the use of PArallel Protein Information Analysis (PAPIA) system (http://
cbrc3.cbrc.jp/papia/), parallel calculation using EnterPrise 4000 with 250 MHz UltraSPARC 
II 9pu, at the Computational Biology Research Center, AIST [26, 27]. The computing strat-
egies employed were Chou-Fasman algorithm, and the joint prediction method where the 
protein secondary structure results of five different independent prediction methods were 
evaluated. In the latter calculation, the most likely secondary structure element for each amino 
acid sequence region of interest is decided from five independent answers depending on the 
decision by majority. The five methods incorporated are Qian-Sejnowski, Ptitsyn-Finkelstein, 
Nisikawa-Ooi, SSthread (prediction of protein secondary structure using threading), and 
Gibrat-Garinier-Robson methods. They were chosen from different methodologies on the 
basis of their performance.
3. Results and discussion
3.1. Characterization of sCR1 binding affinity for C3b
The intrinsic state, that is, if the protein is in the original structural state, its activity should 
be retained. Therefore, it can be considered that the purified protein assumes the same three-
dimensional structure as when it is present in vivo. The binding affinity of the overproduced 
and purified human sCR1 for the complement C3b was investigated by biophysical interaction 
analysis with BIACORE X. The scheme in Figure 2(a) shows an outline of the measurement, 
and Figure 2(b) shows one of the typical results of sensorgram. In the light of the manufac-
ture’s protocol for data analysis, we have analyzed the data on the assumption of hetero-
geneous ligand parallel reaction and found that the dissociation constants of sCR prepared 
according to our production and purification method were Kd = 3.03 × 10−10 M for C3d dimer, 
and Kd = 4.59 × 10−9 M for C3b monomer, which are higher affinity than any values reported 
so far [18, 28–32]. It turned out that the binding affinities for C3b of the sCR1 prepared by our 
developed procedure are remarkably strong. We consider that the reason is due to the rapid 
and efficient purification method developed by us that can preserve sCR1 in an intact state.
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3.2. Characterization of sCR1 suppression effect of cell necrosis
In order to investigate the suppression effect of sCR1 on complement activation, a stroma cell 
PA-6 derived from mouse skull bone marrow was used for the assay. Human serum com-
prises complement proteins C1–C9, which trigger the activation of complement pathways 
and attack invading target microbes or non-self-cells. The complement pathway ends with the 
Figure 2. (a) A schematic drawing of the binding assay measurement by BIACORE. In complement C3b solution used 
as an analyte, monomeric and dimeric forms in C3b are recognized. The existence ratio between C3b monomer and C3b 
dimer was confirmed on HPLC gel permeation column chromatography. (b) A typical result of sensorgram from the 
biophysical interaction analysis with BIACORE X.
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necrosis of target cells due to the attack by C5b-9 membrane attack complex (MAC) [22, 23]. 
MAC is an important innate immune effector of the complement terminal pathway that 
forms cytotoxic pores on the surface of microbes. Similarly to CR1, the conformation in three-
dimension of MAC is also unknown. In order to determine whether the purified human sCR1 
retains its activity to bind complement C3b and/or C4b and suppresses the necrosis of cells by 
blocking complement pathway, sCR1 was added to PA-6 cells before the addition of the nor-
mal human serum (NHS). The results are shown in Figure 3. Cells cultured in medium were 
used as a control (Figure 3(a)), and cells cultured with inactivated NHS show similar results 
as the control; all cells grew well and maintained their normal morphology (Figure 3(b)). 
This fact implies that the inactivated complements in the serum cannot trigger any comple-
ment pathway. However, cells cultured with NHS reveal remarkable necrosis (Figure 3(c)). 
It implies that NHS triggers the activation of complement pathway and MAC attacks the cell 
membrane and causes cell death. On the other hand, when cells were cultured in the presence 
of NHS as well as the purified sCR1, cells showed normal morphology without any necrosis 
although most of cells appeared slim in their shape (Figure 3(d)). These results proved that 
the purified sCR1 has an activity to bind C3b and C4b in NHS and play a role as a blocker to 
the activation of MAC.
Figure 3. Suppression effect of cell necrosis by sCR1 on stroma cell PA-6. Phase contrast micrographs of PA-6 cells 
in (a) α-MEM media (control), (b) in the presence of heat inactivated NHS, (c) in the presence of NHS, and (d) in the 
presence of NHS plus the purified sCR1. Cell necrosis is observed when the formation of membrane attack complex 
(MAC) located at the complement terminal pathway is not inhibited. The scale bars correspond to 100 μm.
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3.3. Crystallization trials
Although we have not yet fully succeeded in obtaining crystals of sCR1 suitable for X-ray crys-
tallographic experiments, the microcrystals have been obtained more than 10 years after the 
continuous re-innovation of cell culture methods and protein purification strategies. Figure 4  
shows the micrographs of thus obtained microcrystals of sCR1. These crystals are obtained 
under the conditions where sulfate and polyethylene glycol (PEG) of low polymerization degree 
were used as precipitants (Kato and Ishii, unpublished data). Those microcrystals diffract X-ray 
up to several tens of angstrom units, only in a small angle region (data not shown) [33].
Furtado et al. reported the structural model as a partly folded back solution structure of human 
sCR1 by using a combination of small angle X-ray scattering and analytical ultracentrifugation 
analyses [34]. They constructed the sCR1 model using a SCR segment as a building block unit. 
The average model of the consensus SCR domain used was derived from 27 different experi-
mental SCR structural templates and 49 residue consensus SCR sequence from 124 human 
complement sequences. They connected the SCRs and build the sCR1 model so as to give a 
better hit to the X-ray solution scattering profiles. Although they emphasize that one out of the 
five models is the most likely conformation in a free environment, these five models do not 
seem to overlap three-dimensionally with each other at all. Their solution structure of human 
sCR1 reported appears not to be rigid at each inter-SCR connection. The realization of structure 
Figure 4. Microcrystals of human sCR1. Approximate dimension of the typical crystals were 29 × 29 × 33 μm. The scale 
bar in panel (a) corresponds 100 μm, and that for the enlargement, (b)–(d) corresponds 50 μm. Those microcrystals 
diffract X-ray poorly and spots could be recorded in a small angle range (not shown).
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at an atomic resolution of human sCR1 as determined with X-ray crystallography appears very 
difficult without once forming a rigid complex structure with a complement ligand like C3b, 
although it is unknown what three-dimensional structured complex would be formed between 
sCR1 and C3b.
3.4. Secondary structure simulation of human sCR1
To change tactics, it may be useful to compute the secondary structure prediction for the amino 
acid sequence of a protein whose tertiary structure is not determined [26]. First, we tried the pre-
diction method of Chou-Fasman. The results of secondary prediction for each SCR (from SCR-1 
through SCR-30) are exhibited in Figure 5. According to the Chou-Fasman method, the content 
of α-helices is 13.6%, and that of β-strands is 24.9%. Taking a look at the distribution along the 
sequences of the predicted secondary elements, similarity is recognized between every seventh 
SCRs. Typically, the homogeneity among the every seventh SCRs between SCR-8–SCR-11 and 
SCR-15–SCR-18 are remarkable. These regions are considered as a C3b/C4b binding site, thus 
the conservation in the secondary elements between the above regions is convincible consistent 
with this observation.
The structural model of the domain from SCR-15 through SCR-17 of human sCR1 was built by 
Smith et al. [35]. Before building the structural model of the three consecutive SCR domains, 
they had determined the solution structure of SCR-15–SCR-16, and SCR-16–SCR-17, inde-
pendently by NMR analyses. As shown in Figure 6(a), the model reveals three complement 
control modules (SCR-15–17) in extended head-to-tail arrangement with flexibility at the SCR-
15–SCR-16, and the SCR-16–SCR-17 junction. Figure 6(b) shows the result of quantitative elec-
trostatic calculations. The view orientation is the same as Figure 6(a). In this view angle, the 
negatively charged surface regions appear to be dominant and appear to be concentrated on 
the surface of SCR-15, and SCR-17. Figure 6(c) is a presentation of SCR-15–16–17 from a dif-
ferent orientation (turned 180°) as shown on the right side of Figure 6(b). The corresponding 
electrostatics to Figure 6(c) is shown in Figure 6(d). At this angle, the positively charged sur-
face regions appear to be connected with one-side surface of SCR-15 through SCR-17. It is said 
that the positively charged region on SCR-15 is critical for C4b binding, and further, together 
with basic amino acid residues exposed on the same surface of SCR-16 are requisite for C3b 
binding [35]. Negatively charged regions are also seen scattered on the surface. The domain 
architecture and the manner of charged states appear important and may provide clues to the 
functional aspect of C3b binding.
At this stage, it appears interesting to examine the secondary structure predictions with the 
model built from the solution structures by NMR analyses. The domain SCR-15–17 (indi-
cated with a box in Figure 5) is from a prediction using the Chou-Fasman method (Figure 5). 
α-Helices are not assigned with the solution structure at all (Figure 6), though the existence 
is predicted by the Chou-Fasman method. However, it is interesting that the number of pre-
dicted secondary structural elements is almost comparable. We then tried another structure 
prediction method, that is, the joint prediction method, which had higher precision. Figure 7 
shows the results of secondary prediction for each SCR (from SCR-1 through SCR-30) by the 
use of the joint prediction method. The content of α-helices is 6.0%, and that of β-strands is 
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Figure 5. Secondary structure prediction for each SCR (from SCR-1 through SCR-30) in human sCR1 by the use of the 
Chou-Fasman method. The sequence predicted as α-helix or β-strand is shown with a cylindrical shape or fat arrow, 
respectively. The predicted sequence except the secondary structural element is a coil shown as a simple rod. The conserved 
Cys residues in each SCR are highlighted in red. The portion of SCR-15–17 discussed in the text is indicated with a box.
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19.3%. The accuracy of results from the joint prediction methods is better than a single method 
such as Chou-Fasman method, Garinier-Osguthorpe-Robson method, and Lim method [27]. 
Since the final assessment of whether a certain amino acid sequence forms a secondary struc-
ture element is determined by majority rule between five different prediction algorithms, the 
precision success rate is rather high while the adoption rate as secondary structure elements is 
low compared to the prediction results by Chou-Fasman method on the whole. Looking at the 
prediction of SCR-15–17 for example (as indicated with a box in Figure 7), all but one predicted 
secondary elements as β-strands, suggesting that precision rose. The content of α-helices was 
predicted in the half ratio in comparison with that of β-strands by the Chou-Fasman method, 
but the prediction of α-helices improved in one-third or less compared with the content of 
β-strands using the joint method. In the algorithms of the joint prediction method, the most 
likely secondary structure element for each amino acid sequence region is decided depending 
Figure 6. Diagrams of solution structure of domains SCR-15–17 (PDB ID: 1GOP). (a) Cα trace of SCR-15–17 with secondary 
structural elements (β-strand is indicated with arrow) and disulfide bonds (indicated with spheres). (b) An electrostatic 
presentation of SCR-15–17; the same view as (a). The protein domains are shown as an electrostatic surface colored blue in 
the positive regions and red in the negative regions. (c) Cα trace with secondary structural elements and disulfide bonds 
of SCR-15–17 made to rotate 180° as shown on the right side of (b). (d) An electrostatic presentation of SCR-15–17; the 
same view as (c). Atomic coordinates were obtained from the RCSB protein data Bank (www.rcsb.org/pdb/home/home.
do) and imaged using PyMol (the PyMOL molecular graphics system, version 0.99, DeLano scientific, LLC).
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Figure 7. Secondary structure prediction for each SCR (from SCR-1 through SCR-30) in human sCR1 by the use of the 
joint prediction method. The sequence predicted as α-helix or β-strand is shown with a cylindrical shape or fat arrow, 
respectively. The predicted sequence except the secondary structural element is a coil shown as a simple rod. The conserved 
Cys residues in each SCR are highlighted in red. The portion of SCR-15–17 discussed in the text is indicated with a box.
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on the decision by majority votes against five independent answers, from Qian-Sejnowski, 
Ptitsyn-Finkelstein, Nisikawa-Ooi, SSthread, and Gibrat-Garinier-Robson methods. Therefore, 
a sequence will not be qualified as a secondary structure, either α-helix or β-strand, unless 
getting an approval from majority solutions. Therefore, the number of region predicted as 
secondary structured elements as a whole will be decreased, but higher reliability will be 
expected. The tendencies in the order and distribution of the predicted secondary elements 
are recognized to be almost the same between every seventh SCRs, especially among the every 
seventh SCRs between SCR-8–SCR-11 and SCR-15–SCR-18.
3.5. Structural biological aspect of human sCR1
As discussed earlier, determinations of three-dimensional structure of each SCR, and the 
confidence with subsequent modeling of sCR1 appears severely difficult due to the sequence 
variation, and the orientation and flexibility of neighboring SCRs with respect to one another 
appear to easily change considerably, and are thus unpredictable. sCR1 is one of the very dif-
ficult targets for structure analysis, but we are convinced that such a goal has some promise 
once its three-dimensional molecular structure is determined.
Recently, a large number of NUPs have been found, and those appear to be connected with 
signaling and regulation of gene expression [8]. As exemplified above with sCR1, there are a 
lot of proteins involved in the immune system whose three-dimensional structure has not yet 
been revealed by X-ray crystallography. One of the reasons is the difficulties in the preparation 
of crystals suitable for X-ray diffraction methods probably due to the large flexibility (that may 
correspond to large values in B factor) of functional and reactive domains and is thus subject to 
conformational changes. The conceptual importance of NUPs is that various proteins interact 
with other proteins via intrinsically disordered regions. It means the ID region is an unfolded 
state without a definitive structure, but when a ligand peptide or partner protein coexists, the 
region interacts with it to form a complex by changing the random coil segments to second-
ary structures. It is suggested that disorder in a free state may actually be advantageous for the 
binding process, and that the rate of macromolecular association is enhanced by the presence of 
disorder region [36, 37]. As a way out of the situation, co-crystallization with some sort of ligands 
may work. That is, we should utilize the property of NUPs-like protein that is easy to change 
conformations by letting the protein change its structures, and by guiding it to a structure that 
is easier to be crystallized. The structural atlas of the protein promotes and deepens an under-
standing of the interaction between the complement proteins, which are involved in the human 
immune system, and drives novel drug development. Direct structural studies of the interaction 
between C4b and sCR1, or between C3b and sCR1 are desired to realize these goals [38].
4. Conclusions
Proteins like sCR1 are difficult targets to lead crystallization suitable for X-ray crystallogra-
phy. The recognition of NUPs has imposed the view that proteins consist not only of struc-
tured domains but also of ID regions. The ID region is an unfolded state without a definitive 
structure, but when a ligand peptide or partner protein coexists, the region interacts with it 
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to form a complex by changing the random coil segments to rigid structured secondary struc-
tures. As a way out of the situation, co-crystallization with some sort of ligands or partner 
protein molecule may work. That is, we should utilize the flexible conformation property of 
NUPs-like protein, let the protein change its structures, and guide it to the structure that is 
easy to be crystallized. Once the structural detail of interest is obtained at hand, the atlas of the 
protein promotes and deepens the understanding of the interaction between the complement 
proteins which are involved in the immune system.
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